The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Inhaled Corticosteroids in Children with Asthma: Pharmacologic Determinants of Safety and Efficacy and Other Clinical Considerations
Abstract
The role of inhaled corticosteroids (ICS) in the treatment of childhood asthma has been well established. An ideal corticosteroid should demonstrate high pulmonary deposition and residency time, in addition to a low systemic bioavailability and rapid systemic clearance. The lung depositions of the ICS have been compared, with beclomethasone (beclometasone)-hydrofluoroalkane (HFA) and ciclesonide showing the highest lung deposition. Lung deposition is influenced by not only the inhalation device and type of propellant (HFA or chlorofluorocarbon), but also by whether the aerosol is a solution or suspension, and the particle size of the respirable fraction. Pulmonary residency time increases when budesonide and des-ciclesonide undergo reversible fatty acid esterification. The bioavailability of the drug depends on the oral bioavailable fraction and the amount absorbed directly from the pulmonary vasculature. The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms. Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%). The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide. Increasing the Vd will also increase the elimination half-life of a drug. The pharmacodynamics of ICS depend on both the receptor binding affinity and the dose-response curve. Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100). Compared with other nonsteroid asthma medications (long-acting beta-agonists, theophylline, and montelukast) ICS have proven superiority in improving lung function, symptom-free days, and inflammatory markers. One study suggests that early intervention with ICS reduces the loss in lung function (forced expiratory volume in 1 second) over 3 years. Whether airway remodeling is reduced or prevented in the long term is unknown. Potential adverse drug effects of ICS include adrenal and growth suppression. While in low-to-medium doses ICS have shown little suppression of the adrenal pituitary axis, in high doses the potential for significant adrenal suppression and adrenal crisis exists. Several longitudinal studies evaluating the effect of ICS on growth have shown a small decrement in growth velocity (approximate 1-2 cm) during the first year of treatment. However, when investigators followed children treated with budesonide for up to 10 years, no change in target adult height was noted. In conclusion, the development of optimal delivery devices for young children, as well as optimizing favorable pharmacokinetic properties of ICS should be priorities for future childhood asthma management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although dexamethasone, a type of corticosteroids, is used for acute exacerbations of asthma, there are multiple adverse effects of this drug including adrenal and growth suppression [32].”
In the citing paper
“The remaining portion of the inhaled compound is usually swallowed, absorbed by the gastrointestinal tract, and it can remain bioavailable after the first liver pass.”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [37]
In the citing paper
“However, this is not fully true: in fact, after inhalation, the amount that reaches the lungs is absorbed into the bloodstream and, in most cases, it is not metabolized to biologically-inactive compounds by the respiratory tract [37].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [37]
Citations
Cites
The global burden of asthma: executive summary of the GINA Dissemination Committee Report
Masoli, M., Fabian, D., Holt, S., Beasley, R., & Program, G. I. F. A. (. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00526.x · Cited by 3,529
Tanner, J. M., & Whitehouse, R. H. (1976) · Archives of Disease in Childhood · doi:10.1136/adc.51.3.170 · Cited by 3,137 · cited 1×
“[100] However, while keeping the frequency and severity of asthma symptoms at long-term data are absolutely needed to ascertain the full effects of bay.”
BackgroundPharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
National Asthma Education and Prevention Program
VanGraafeiland, B. (2002) · The Nurse Practitioner · doi:10.1097/00006205-200206001-00003 · Cited by 1,091
Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma
Guilbert, T. W., Morgan, W. J., Zeiger, R. S., Mauger, D. T., Boehmer, S. J., Szefler, S. J., Bacharier, L. B., Lemanske, R. F., Strunk, R. C., Allen, D. B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051378 · Cited by 1,054
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Agertoft, L., & Pedersen, S. (1994) · Respiratory Medicine · doi:10.1016/0954-6111(94)90044-2 · Cited by 756
Efficacy and Safety of Inhaled Corticosteroids: New Developments
BARNES, P. J., PEDERSEN, S., & BUSSE, W. W. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.3.157315 · Cited by 749
Oelkers, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351607 · Cited by 737
Significant variability in response to inhaled corticosteroids for persistent asthma
Szefler, S. J., Martin, R. J., King, T. S., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Craig, T. J., Dolovich, M., Drazen, J. M., Fagan, J. K., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.122635 · Cited by 622
Research works printed but not linked: 6
- Ryrfeldt, 1982, Eur J Respir Dis Suppl, 122, 86
- Kelly, 1999, Respir Care Clin N Am, 5, 537
- Griffioen, 1998, Ned Tijdschr Geneeskd, 142, 1484
- Miller-Larsson, 2003, Am J Respir Crit Care Med, 167, A773
- Tunek, 1997, Drug Metab Dispos, 25, 1311
- Derendorf, 2005, Allergy Asthma Proc, 26, 89
Cited by
Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181
Ahmet, A., Kim, H., & Spier, S. (2011) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-7-13 · Cited by 114
Andreae, D. A., Hanna, M. G., Magid, M. S., Malerba, S., Andreae, M. H., Bagiella, E., & Chehade, M. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.238 · Cited by 112
Leach, C., Bethke, T. D., Boudreau, R. J., Hasselquist, B. E., Drollmann, A., Davidson, P., & Wurst, W. (2006) · Journal of Aerosol Medicine · doi:10.1089/jam.2006.19.117 · Cited by 91
Ari, A., & Fink, J. B. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.49 · Cited by 87
Metadata
- Authors
- Gulliver, T., Morton, R., & Eid, N.
- Affiliations
- John Hunter Children's Hospital (AU)
- University of Louisville (US)
- Corresponding author
- Eid, Nemr
- ORCID
- Morton, Ronald
- Venue
- Pediatric Drugs
- Published
- 2007
- Volume
- 9
- Issue
- 3
- Pages
- 185-194
- ISSN
- 1174-5878 (ISSN-L)
- OpenAlex
- W613309803
- Cited by
- 47
- References
- 100
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2021: 2 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 1 · 2013: 2 · 2012: 6
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pediatric Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Standards and Technology
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- inhaled corticosteroids, childhood asthma, lung deposition, beclomethasone, ciclesonide, mometasone, fluticasone, budesonide, pharmacokinetics, pharmacodynamics, adrenal suppression, growth inhibition, airway remodeling, long-acting beta2-agonists, corticosteroid adverse effects
- MeSH terms
- Administration, Inhalation, Adrenal Cortex Hormones, Asthma, Child, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled Corticosteroids in Children with Asthma: Pharmacologic Determinants of Safety and Efficacy and Other Clinical Considerations. https://app.cochat.ai/papers/10.2165/00148581-200709030-00007
- The paper
- Gulliver, T., Morton, R., & Eid, N. (2007). Inhaled Corticosteroids in Children with Asthma: Pharmacologic Determinants of Safety and Efficacy and Other Clinical Considerations. Pediatric Drugs. https://doi.org/10.2165/00148581-200709030-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.